NCT04862260View on ClinicalTrials.gov

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2026

Conditions
Pancreatic Ductal AdenocarcinomaPancreatic CancerPancreas CancerMetastatic Cancer
Interventions
DRUG

Cholesterol metabolism disruption

Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas

Trial Locations (2)

H2X 0A9

CHUM, Montreal

G1R 2J6

CHU de Québec-Université Laval, Québec

Sponsors

Collaborators (1)

Biovalorem
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Biovalorem

UNKNOWN

lead

CHU de Quebec-Universite Laval

OTHER